Prostate cancer (PC) is the second most frequently diagnosed cancer and the second leading cause of cancer deaths in man.
The treatment of localized PC includes surgery or radiation therapy. In case of relapse after a definitive treatment or in patients with locally advanced or metastatic disease, the standard treatment includes the androgen-deprivation therapy (ADT). By reducing the levels of testosterone and dihydrotestosterone under the castration threshold, the ADT acts on the androgen receptor (AR), even if indirectly. The effects of the ADT are usually temporary and nearly all patients, initially sensitive to the androgen ablation therapy, have a disease progression after an 18-24 months medium term. This is probably due to the selection of the cancer cell clones and to their acquisition of critical somatic genome and epigenomic changes. This review aims to provide an overview about the genetic and epigenetic alterations having a crucial role in the carcinogenesis and in the disease progression toward the castration resistant PC. We focused on the role of the AR, on its signaling cascade and on the clinical implications that the knowledge of these aspects would have on hormonal therapy, on its failure and its toxicity.
Written by:
Aschelter AM, Giacinti S, Caporello P, Marchetti P. Are you the author?
Department of Oncology, Sant'Andrea Hospital, "Sapienza" University of Rome Rome, Italy.
Reference: Front Endocrinol (Lausanne). 2012;3:128.
doi: 10.3389/fendo.2012.00128
PubMed Abstract
PMID: 23133437
UroToday.com Investigative Urology Section
